Interstitial lung disease in scleroderma

Rheumatic Disease Clinics of North America

Volumn 29, Issue 2, 2003, Pages 371-390

  White, Barbara ^a,b  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CARBON DIOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GALLIUM; GAMMA INTERFERON; OXYGEN; PENICILLAMINE; PENTETATE TECHNETIUM TC 99M; PREDNISOLONE; SCL 70 ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; INTERSTITIAL LUNG DISEASE; LEUKOCYTE DIFFERENTIAL COUNT; LUNG BIOPSY; LUNG CLEARANCE; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; LUNG TRANSPLANTATION; LUNG VOLUME; OXYGEN THERAPY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCLERODERMA; STEM CELL TRANSPLANTATION; SURVIVAL; SYNDROME CREST; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; TREATMENT INDICATION;

EID: 0038799767     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00025-5     Document Type: Review

References (81)

1. Jacobsen S, Halberg P, Ullman S, et al. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol 1997;16(4):384-90.
2. Steen VD, Owens GR, Fino GJ, et al. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985;28(7):759-67.
3. Griedinger EL, Flaherty KT, White B, et al. African American race and antibodies to topisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998;114:801-7.
4. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37(9):1283-9.
5. Garber SJ, Wells AU, duBois RM, et al. Enlarged mediastinal lymph nodes in the fibrosing alveolitis of systemic sclerosis. Br J Radiol 1992;65(779):983-6.
6. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990;176(3):755-9.
7. Owens GR, Fino GJ, Herbert DL, et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983;84(5):546-50.
8. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997;24(1):81-5.
9. Steen VD, Ziegler GL, Rodnan GP, et al. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984;27(2):125-31.
10. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28(11):2454-9.
11. Catoggio LJ, Bernstein RM, Black CM, et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983;42(1):23-37.
12. Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338(8768):661-2.
13. Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999;116(3):715-20.
14. Rizou C, Ioannidis JP, Panou-Pomonis E, et al. B-cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis. Am J Respir Cell Mol Biol 2000;22(3):344-51.
15. Steen VD, Graham G, Conte C, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35(7):765-70.
16. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43(11):2437-44.
17. Peters-Golden M, Wise RA, Hochberg MC, et al. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984;77(6):1027-34.
18. Bhalla M, Silver RM, Shepard JA, et al. Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. Am J Roentgenol 1993;161(2):269-72.
19. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001;45(4):346-54.
20. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132(12):947-54.
21. Wells AU, Lorimer S, Majumdar S, et al. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 1995;8(2):266-71.
22. Kuwana M, Kaburaki J, Arnett FC, et al. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42(3):465-74.
23. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia, Sarcoidosis Vasc Diffuse Lung Dis 2002;19(2):121-7.
24. Altman RD, Medsger Jr TA, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
25. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002;41(6):676-9.
26. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum 2003;62(2):146-50.
27. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165(12):1581-6.
28. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997;40(7):1229-36.
29. Renzoni E, Lympany P, Sestini P, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000;43(7):1633-40.
30. Zhou X, Tan FK, Reveille JD, et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 2002;46(11):2990-9.
31. Avila JJ, Lympany PA, Pantelidis P, et al. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999;20(1):106-12.
32. Hasegawa M, Sato S, Ihn H, et al. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999;38(7):612-7.
33. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (M1P-1alpha) and M1P-1beta) in patients with systemic sclerosis: MCP-1 and M1P-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117(1):159-65.
34. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000;27(1):149-54.
35. Yazawa N, Kikuchi K, Ihn H, et al. Serum levels of tissue inhibitor of metalloproteinase 2 in patients with systemic sclerosis. J Am Acad Dermatol 2000;42(1)(Pt 1):70-5.
36. Asano Y, Ihn H, Yamane K, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001;44(6):1363-9.
37. Yamane K, Ihn H, Kubo M, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000;27(4):930-4.
38. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991;144(3)(Pt 1):706-13.
39. Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88(5):470.
40. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20(5):838-44.
41. Witt C, Borges AC, John M, et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999;58(10):635-40.
42. Atamas SP, Yurovsky VV, Wise R, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42(6):1168-78.
43. Rossi GA, Bitterman PB, Rennard SI, et al. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 1985;131(4):612-61.
44. Seyer JM, Lkang AH, Rodnan G. Investigations of type I and type III collagens in the lung in progressive systemic sclerosis. Arthritis Rheum 1981;24:625-31.
45. Kinsella MB, Smith EA, Miller KS, et al. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum 1989;32(5):577-83.
46. Luzina IG, Atamas SP, Wise R, et al. Functional patterns of gene expression in scleroderma patients with and without lung inflammation. Am J Respir Cell Mol Biol 2002;26:549-57.
47. Taylor ML, Noble PW, White B, et al. Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. Clin Immunol 2000;94:33-41.
48. Majumdar S, Li D, Ansari T, et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14(2):251-7.
49. Coker RK, Laurent GJ, Jeffery PK, et al. Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax 2001;56(7):549-56.
50. Corrin B, Butcher D, McAnulty BJ, et al. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24(2):145-50.
51. Deguchi Y, Kishimoto S. Spontaneous activation of transforming growth factor-beta gene transcription in broncho-alveolar mononuclear cells of individuals with systemic autoimmune diseases with lung involvement. Lupus 1991;1(1):27-30.
52. Ludwicka A, Ohba T, Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995;22(10):1876-83.
53. Ohba T, McDonald JK, Silver RM, et al. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. Am J Respir Cell Mol Biol 1994;10(4):405-12.
54. Ludwicka A, Trojanowska M, Smith EA, et al. Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma. J Rheumatol 1992;19(11):1716-23.
55. Sappino AP, Masouye I, Saurat JH, et al. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990;137(3):585-91.
56. Shi-Wen X, Denton CP, McWhirter A, et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum 1997;40(7):1237-44.
57. Bridges AJ, Hsu KC, Dias-Arias AA, et al. Bronchiolitis obliterans organizing pneumonia and scleroderma. J Rheumatol 1992;19(7):1136-40.
58. Pignone A, Matucci-Cerinic M, Lombardi A, et al. High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation. Clin Rheumatol 1992;11(4):465-72.
59. Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991;18(10):1520-8.
60. Andonopoulos AP, Yarmenitis S, Georgiou P, et al. Bronchiectasis in systemic sclerosis. A study using high resolution computed tomography. Clin Exp Rheumatol 2001;19(2):187-90.
61. Devenyi K, Czirjak L. High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma. Clin Rheumatol 1995;14(6):633-40.
62. Kim EA, Johkoh T, Lee KS, et al. Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. J Comput Assist Tomogr 2001;25(5):757-63.
63. Wechsler RJ, Steiner RM, Spirn PW, et al. The relationship of the thoracic lymphadenopathy to pulmonary interstitial disease in diffuse and limited systemic sclerosis: CT findings. AJR Am J Roentgenol 1996;167:101-4.
64. Clements PJ, Tashkin D, Roth M, et al. Concordance of HRCT and BAL at entry into the scleroderma-lung study (SLS). Arthritis Rheum 2002;46:S356.
65. Kon OM, Daniil Z, Black CM, et al. Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J 1999;13(1):133-6.
66. Baron M, Feiglin D, Hyland R, et al. 67Gallium lung scans in progressive systemic sclerosis. Arthritis Rheum 1983;26(8):969-74.
67. Furst DE, Davis JA, Clements PJ, et al. Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. Arthritis Rheum 1981;24(11):1403-8.
68. Ing AJ. Interstitial lung disease and gastroesophageal reflux. Am J Med 2001;111(Suppl 8A):41S-4S.
69. Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999;18(6):455-61.
70. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29(4):731-6.
71. Pakas I, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29(2):298-304.
72. Steen VD, Lanz Jr JK, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994;37(9):1290-6.
73. Varai G, Earle L, Jimenez SA, et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998;25(7):1325-9.
74. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341(17):1264-9.
75. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42(2):299-305.
76. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42(6):1194-203.
77. Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000;5(3):38-43.
78. Schachna L, Braunstein NA, Dauber JH, et al. Lung transplantation for systemic scleroderis compared with idiopathic pulmonary fibrosis: increased early mortality but comparable survival at one year. Arthritis Rheum 2002;46:S382.
79. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60(6):577-84.
80. Viganego F, Nash R, McSwenney P, et al. Course of alveolitis in severe systemic sclerosis (SSc) after autologous stem cell transplantation. Arthritis Rheum 2002;46:S382.
81. Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002;119(3):226-39.